SELLAS Life Sciences Group, Inc. announced positive topline results from the pivotal randomized Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, in patients with acute myeloid leukemia (AML).

The trial evaluated GPS as maintenance monotherapy in patients who achieved a second or later complete remission (CR2 or later) or complete remission with insufficient platelet recovery (CRp2 or later) following second- or later-line salvage therapy and were ineligible for or unable to undergo allogeneic stem cell transplantation.

The REGAL trial met its primary endpoint of overall survival (OS). GPS demonstrated a statistically significant improvement in OS compared to the investigator's choice of best available treatment (BAT). The data showed a 41% reduction in the risk of death, with a hazard ratio of 0.59 and a two-sided p-value of 0.035. Median OS was 24.0 months among GPS-treated patients compared to 14.7 months with BAT.

GPS was generally well tolerated, with a safety profile consistent with prior clinical experience and no new safety signals identified. Treatment-related adverse events were predominantly mild to moderate (grade 1/2), most commonly consisting of local injection site reactions.

The trial randomized 126 patients 1:1 to receive GPS monotherapy or BAT, which included observation, hypomethylating agents, venetoclax, and/or low-dose cytarabine. Both treatment arms were well balanced for prognostic stratification factors.

SELLAS plans to meet with the U.S. Food and Drug Administration (FDA) to discuss an accelerated filing strategy and advance preparations for a Biologics License Application (BLA) submission for GPS in the first half of 2027.